PIK3CA and neoplasm: Although treatment with Alpelisib (BYL-719) was able to inhibit the proliferation of all the cell lines tested, indicating that p110α is indeed involved in sustaining tumor cell proliferation, when combined with Idelalisib (CAL-101), a PI3K p110δ specific inhibitor, the Alpelisib–Idelalisib combination showed a stronger anti-proliferative effect with respect to both the use of single inhibitor and the administration of the double inhibitor AZD8835, as demonstrated by the lower IC50.